

Index to Volume 10

The index to Volume 10 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *Clinical Pharmacy* as "index terms" after abstracts.) IPA covers all authored papers and editorials in *Clinical*

Pharmacy, as well as selected letters and news reports. The subject index also notes all regular columns and, under the respective column headings, the titles of items in the "News," "Therapy Consultation," "Letters," "Editorials," and "Book Reviews" sections. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages	Issue	Pages
January	1-80	July	483-566
February	81-160	August	567-650
March	161-246	September	651-730
April	247-318	October	731-806
May	319-404	November	807-890
June	405-482	December	891-990

Subject Index

A

- Absorption**
glyburide; effects, age, 532
triazolam; interactions, ranitidine, 539
- Acetaminophen**
osteoarthritis; therapy, geriatrics, ulcer history, 740
pain; therapy, codeine allergies, 658
poisoning; overdose, acetylcysteine therapy, 765
- Acetazolamide**; epilepsy; therapy, review, 335
- Acetimidoloquinone**; metabolites; acetaminophen, toxicity, 765
- Acetylcholinesterase inhibitors**; Alzheimer's disease; therapy, mechanism of action, review, 447
- Acetylcysteine**; therapy; acetaminophen overdose, 765
N-Acetylimidoloquinone; see *Acetimidoloquinone*
- N-Acetyl-D,L-penicillamine**; antidotes; mercury poisoning, pediatrics, 213
- Achlorhydrin**; glutamic acid hydrochloride; effects, gastric pH, 866
- Acinetobacter species**; resistance; ceftazidime, pneumonia, 49
- Acquired immunodeficiency syndrome**
aminoglycosides; pharmacokinetics, 784
pentamidine; toxicity, pancreatitis, hemophilia, 56
therapy; *Mycobacterium avium* complex, review, 280;
research, AIDS conference, 809
- Acyclovir**; herpes zoster; and chickenpox, therapy, HIV infections, 301
- Acyclovir sodium**; herpes zoster; and chickenpox, therapy, HIV infections, 301
- Adrenergic agents**, see *Sympathomimetic agents*
- Adsorbents**; charcoal activated; therapy, impaired phenytoin metabolism, liver diseases, 711
- Adverse drug reactions report form**, 311, 395, 479, 555, 641, 727, 801, 881, 959
- Adverse reactions**, see *Drugs, adverse reactions*
- Advertising Index**, 80, 160, 246, 318, 404, 482, 558, 650, 730, 806, 890, 976
- Age**; geriatrics; glyburide pharmacokinetics, 532
- AIDS**, see *Acquired immunodeficiency syndrome*
- Albumin**; human; nutrition; parenteral, supplements, dosage predictions, pediatrics, 704
- Alcohols, cetyl**; combination, colestcerol palmitate, tyloxapol; vs. beractant, therapeutic equivalence, 909
- Alfentanil**; pharmacology; clinical uses, review, 581
- Alfentanil hydrochloride**; use; review, criteria, quality assurance programs, 635
- Algiglucerase**; marketing; FDA approvals, 496
- Allergies**
codeine; alternative analgesics, 658
laxatives; adverse reactions, FDA recommendations, 417
- Anistreplase**; comparison, anistreplase, streptokinase; myocardial infarction therapy, 486
- Antacids**; use; evaluation, stress ulcer prophylaxis, criteria, 787
- Antianemia drugs**; epoetin; DUE criteria, quality assurance programs, 143, 303
- Antiarrhythmic drugs**, see *Cardiac drugs*
- Ambulatory care**; hypertension; monitoring, devices, assessment, 175
- Amikacin**
Mycobacterium avium complex; therapy, AIDS, review, 280
resistance; gram-negative bacteria, in vitro, 544
- Amino acids**; Alzheimer's disease; therapy, mechanism of action, review, 447
- Aminoglycosides**
amikacin; *Mycobacterium avium* complex, AIDS, 280;
resistance, gram-negative bacteria, in vitro, 544
gentamicin; dosage predictions, pharmacokinetics, methodology, 706; renal function estimation, 931;
pharmacokinetics, AIDS, 784
- Anabolic agents**; steroids; reclassification, controlled substances, 417
- Anabolic Steroids Act of 1990**; laws; reclassification, controlled substances, 417
- Analgesics and antipyretics**
acetaminophen; osteoarthritis therapy, geriatrics, ulcer history, 740; overdose, acetylcysteine therapy, 765
- alfentanil hydrochloride**; DUE criteria, quality assurance programs, 635; review, 581
- codeine**; allergies, alternative therapies, 658
- fentanyl**; FDA approvals, transdermal patches, pain therapy, 9; review, 581
- fentanyl citrate**; DUE criteria, quality assurance programs, 635
- fenfluramine**; DUE criteria, quality assurance programs, 635
- ketorolac tromethamine**; DUE criteria, 715
- pain**; postoperative, therapy, continuous epidural infusions, 745; therapy, pediatrics, 667
- sufentanil**; review, 581
- sufentanil citrate**; DUE criteria, quality assurance programs, 635
- therapy**; alternatives, codeine allergies, 658
- Androgens**; danazol; endometriosis therapy, 518
- Anemia**; epoetin; therapy, kidney failure, DUE criteria, 143, 303
- Anesthetics, local**
pain; postoperative, therapy, continuous epidural infusions, 745; therapy, pediatrics, 667
- Angina pectoris**; cardiac drugs; unstable, therapy, 825
- Angiotensin-converting enzyme inhibitors**
heart failure; congestive, therapy, diastolic dysfunction, 850
- kidney diseases**; therapy, 25
- Anistreplase**; comparison, alteplase, streptokinase; myocardial infarction therapy, 486
- Antacids**; use; evaluation, stress ulcer prophylaxis, criteria, 787
- Antianemia drugs**; epoetin; DUE criteria, quality assurance programs, 143, 303
- Antiarrhythmic drugs**, see *Cardiac drugs*
- Antibiotics**
Mycobacterium avium complex; therapy, AIDS, review, 280
imipenem; susceptibility, amikacin-resistant isolates, in vitro, 544
- vancomycin**; hydrochloride; blood levels, half-life, hepatic and renal dysfunction, 297
- Antibodies**; monoclonal; radionuclides, immunotherapy, neoplasms, 359
- Anticoagulants**
heparin; i.v. infusion sites, toxicity, 630; thromboembolism therapy, guidelines, 503
- warfarin**; interactions, ciprofloxacin, PT effects, lack, 136; nomograms, dosage, predictions, vs. computers, 923; thromboembolism therapy, guidelines, 503
- Anticonvulsants**
epilepsy; therapy, review, 335
- phenytoin**; blood levels, effects, ultrafiltration and freezing, 132; dosage calculations, black African and Indian children, 928
- phenytoin sodium**; impaired metabolism, liver diseases, activated charcoal therapy, 711
- valproate sodium**; syrups, availability, vs. valproic acid emulsions, 382
- valproic acid**; emulsions, availability, vs. valproate sodium syrup, 382
- Antidepressants**; tricyclic; panic disorders therapy, 893
- Antidiabetic agents**; glyburide; pharmacokinetics, effects, age, 532
- Antitoxins**
acetylcysteine; acetaminophen overdose, 765
- digoxin immune Fab**; toxicity, digoxin, 823
- heavy-metal antagonists**; poisoning, pediatrics, 213
- Antiemetics**
ondansetron hydrochloride; DUE criteria, quality assurance programs, 471; pharmacology, review, 430; prophylaxis, chemotherapy toxicity, FDA approvals, 249
- Antifungals**
fluconazole; DUE criteria, quality assurance programs, 222; pharmacology, review, 179
- ketoconazole**; Cushing's syndrome therapy, 12
- Anti-infective agents**
Mycobacterium avium complex; combined therapy, AIDS, review, 280
- pentamidine**; toxicity, pancreatitis, AIDS, 56
- pentamidine isethionate**; infusions, adverse reactions, facial numbness, 257
- Anti-inflammatory agents**
aspirin; osteoarthritis therapy, geriatrics, ulcer history, 740
- etodolac**; osteoarthritis therapy, FDA approvals, 416

Index to Volume 10

The index to Volume 10 is composed of three parts: a subject index, an author index, and an advertising index.

The subject index is made up mainly of terms constructed by *International Pharmaceutical Abstracts*. The IPA index is an alphabetical, open-ended, controlled-vocabulary index that makes use of standardized headings. (The primary index terms for each article are listed routinely in *Clinical Pharmacy* as "index terms" after abstracts.) IPA covers all authored papers and editorials in *Clinical*

Pharmacy, as well as selected letters and news reports. The subject index also notes all regular columns and, under the respective column headings, the titles of items in the "News," "Therapy Consultation," "Letters," "Editorials," and "Book Reviews" sections. The subject index also contains, under the heading "Correction Notices," the title and issue of publication of items for which corrections were printed, as well as the page numbers on which the corrections appear.

Issue	Pages	Issue	Pages
January	1-80	July	483-566
February	81-160	August	567-650
March	161-246	September	651-730
April	247-318	October	731-806
May	319-404	November	807-890
June	405-482	December	891-990

Subject Index

A

- Absorption** glyburide; effects, age, 532
triazolam; interactions, ranitidine, 539
- Acetaminophen** osteoarthritis; therapy, geriatrics, ulcer history, 740
pain; therapy, codeine allergies, 658
poisoning; overdose, acetylcysteine therapy, 765
- Acetazolamide**; epilepsy; therapy, review, 335
- Acetimidoloquinone** metabolites; acetaminophen, toxicity, 765
- Acetylcholinesterase inhibitors**; Alzheimer's disease; therapy, mechanism of action, review, 447
- Acetylcysteine**; therapy; acetaminophen overdose, 765
N-Acetylimidoloquinone; see *Acetimidoloquinone*
- N-Acetyl-D,L-penicillamine**; antidotes; mercury poisoning, pediatrics, 213
- Achlorhydrin**; glutamic acid hydrochloride; effects, gastric pH, 866
- Acinetobacter species**; resistance; ceftazidime, pneumonia, 49
- Acquired immunodeficiency syndrome** amphotericin; pharmacokinetics, 784
pentamidine; toxicity, pancreatitis, hemophilia, 56
therapy; *Mycobacterium avium* complex, review, 280;
research, AIDS conference, 809
- Acyclovir**; herpes zoster; and chickenpox, therapy, HIV infections, 301
- Acyclovir sodium**; herpes zoster; and chickenpox, therapy, HIV infections, 301
- Adrenergic agents**, see *Sympathomimetic agents*
- Adsorbents**; charcoal activated; therapy, impaired phenytoin metabolism, liver diseases, 711
- Adverse drug reactions report form**, 311, 395, 479, 555, 641, 727, 801, 881, 959
- Adverse reactions**, see *Drugs, adverse reactions*
- Advertising Index**, 80, 160, 246, 318, 404, 482, 558, 650, 730, 806, 890, 976
- Age**; geriatrics; glyburide pharmacokinetics, 532
- AIDS**, see *Acquired immunodeficiency syndrome*
- Albumin** human; nutrition; parenteral, supplements, dosage predictions, pediatrics, 704
- Alcohols, cetyl**; combination, colestcerol palmitate, tyloxapol; vs. beractant, therapeutic equivalence, 909
- Alfentanil**; pharmacology; clinical uses, review, 581
- Alfentanil hydrochloride**; use; review, criteria, quality assurance programs, 635
- Alguracel**; marketing; FDA approvals, 496
- Allergies** codeine; alternative analgesics, 658
laxatives; adverse reactions, FDA recommendations, 417
- Anistreplase**; comparison, anistreplase, streptokinase; myocardial infarction therapy, 486
- Antacids**; use; evaluation, stress ulcer prophylaxis, criteria, 787
- Antianemia drugs**; epoetin; DUE criteria, quality assurance programs, 143, 303
- Antiarrhythmic drugs**, see *Cardiac drugs*
- Ambulatory care**; hypertension; monitoring, devices, assessment, 175
- Amikacin** *Mycobacterium avium* complex; therapy, AIDS, review, 280
resistance; gram-negative bacteria, in vitro, 544
- Amino acids**; Alzheimer's disease; therapy, mechanism of action, review, 447
- Aminoglycosides** amikacin; *Mycobacterium avium* complex, AIDS, 280;
resistance, gram-negative bacteria, in vitro, 544
gentamicin; dosage predictions, pharmacokinetics, methodology, 706; renal function estimation, 931;
pharmacokinetics, AIDS, 784
- Anabolic agents**; steroids; reclassification, controlled substances, 417
- Anabolic Steroids Act of 1990**; laws; reclassification, controlled substances, 417
- Analgesics and antipyretics** acetaminophen; osteoarthritis therapy, geriatrics, ulcer history, 740; overdose, acetylcysteine therapy, 765
- alfentanil hydrochloride**; DUE criteria, quality assurance programs, 635; review, 581
- codeine**; allergies, alternative therapies, 658
- fentanyl**; FDA approvals, transdermal patches, pain therapy, 9; review, 581
- fentanyl citrate**; DUE criteria, quality assurance programs, 635
- fenoldopam tromethamine**; DUE criteria, 715
- pain**; postoperative, therapy, continuous epidural infusions, 745; therapy, pediatrics, 667
- sufentanil**; review, 581
- sufentanil citrate**; DUE criteria, quality assurance programs, 635
- therapy**; alternatives, codeine allergies, 658
- Androgens**; danazol; endometriosis therapy, 518
- Anemia**; epoetin; therapy, kidney failure, DUE criteria, 143, 303
- Anesthetics, local** pain; postoperative, therapy, continuous epidural infusions, 745; therapy, pediatrics, 667
- Angina pectoris**; cardiac drugs; unstable, therapy, 825
- Angiotensin-converting enzyme inhibitors** heart failure; congestive, therapy, diastolic dysfunction, 850
- kidney diseases**; therapy, 25
- Anistreplase**; comparison, alteplase, streptokinase; myocardial infarction therapy, 486
- Antacids**; use; evaluation, stress ulcer prophylaxis, criteria, 787
- Antianemia drugs**; epoetin; DUE criteria, quality assurance programs, 143, 303
- Antiarrhythmic drugs**, see *Cardiac drugs*
- Antibiotics** *Mycobacterium avium* complex; therapy, AIDS, review, 280
imipenem; susceptibility, amikacin-resistant isolates, in vitro, 544
vancomycin hydrochloride; blood levels, half-life, hepatic and renal dysfunction, 297
- Antibodies**; monoclonal; radionuclides, immunotherapy, neoplasms, 359
- Anticoagulants** heparin; i.v. infusion sites, toxicity, 630; thromboembolism therapy, guidelines, 503
warfarin; interactions, ciprofloxacin, PT effects, lack, 136; nomograms, dosage, predictions, vs. computers, 923; thromboembolism therapy, guidelines, 503
- Anticonvulsants** epilepsy; therapy, review, 335
phenytoin; blood levels, effects, ultrafiltration and freezing, 132; dosage calculations, black African and Indian children, 928
phenytoin sodium; impaired metabolism, liver diseases, activated charcoal therapy, 711
valproate sodium; syrups, availability, vs. valproic acid emulsions, 382
valproic acid; emulsions, availability, vs. valproate sodium syrup, 382
- Antidepressants**; tricyclic; panic disorders therapy, 893
- Antidiabetic agents**; glyburide; pharmacokinetics, effects, age, 532
- Antitoxins** acetylcysteine; acetaminophen overdose, 765
digoxin immune Fab; toxicity, digoxin, 823
heavy-metal antagonists; poisoning, pediatrics, 213
- Antiemetics** ondansetron hydrochloride; DUE criteria, quality assurance programs, 471; pharmacology, review, 430; prophylaxis, chemotherapy toxicity, FDA approvals, 249
- Antifungals** fluconazole; DUE criteria, quality assurance programs, 222; pharmacology, review, 179
ketoconazole; Cushing's syndrome therapy, 12
- Anti-infective agents** *Mycobacterium avium* complex; combined therapy, AIDS, review, 280
pentamidine; toxicity, pancreatitis, AIDS, 56
- pentamidine isethionate**; infusions, adverse reactions, facial numbness, 257
- Anti-inflammatory agents** aspirin; osteoarthritis therapy, geriatrics, ulcer history, 740
etodolac; osteoarthritis therapy, FDA approvals, 416

- ibuprofen; interactions, misoprostol, ranitidine, lack, 870; osteoarthritis therapy, geriatrics, ulcer history, 740
- nonsteroidal; pain therapy, codeine allergies, 658
- salsalate; osteoarthritis therapy, geriatrics, ulcer history, 740
- scleroderma; systemic, therapy, 14
- Antilipemic agents**
- cholestyramine resin; palatability, oral formulations, vehicles, 136
 - colestipol hydrochloride; palatability, oral formulations, vehicles, 138
 - hyperlipidemia; therapy, protocols, 943
- Antimanic agents**
- lithium; neutropenia therapy, HIV infections, review, 268
 - lithium carbonate; pharmacokinetics, methodology, models, 376
- Antineoplastic agents**
- fludarabine phosphate; FDA approvals, 496
 - fluorouracil and levensole; colonic neoplasms, combined therapy, 95
 - interleukin 2; renal cell carcinoma, single agent therapy, FDA denial, 141; therapy, review, 110
 - levamisole; colorectal neoplasms therapy, review, 95
 - toxicity; nausea and vomiting, ondansetron prophylaxis, 430; nausea and vomiting, ondansetron therapy, DUE criteria, 471; neutropenia, filgrastim prophylaxis, DUE criteria, 950; neutropenia, filgrastim prophylaxis, FDA approvals, 321; ondansetron prophylaxis, FDA approvals, 249
 - Antithyroid drugs; propylthiouracil; hyperthyroidism therapy, mercury poisoning, 742
- Antivirals**
- acyclovir; chickenpox, herpes zoster therapy, HIV infections, 301
 - zidovudine; toxicity; neutropenia, HIV infections, review, 266
- Anxiolytics, sedatives and hypnotics**
- chloral hydrate; interactions, furosemide, pediatrics, 385
 - lorazepam; dosage, pediatrics, 625
 - midazolam hydrochloride; DUE criteria, quality assurance programs, 388
 - triazolam; interactions, ranitidine, pharmacokinetics, 539
- Arecoline**; Alzheimer's disease; therapy, mechanism of action, review, 447
- Arrhythmia**
- antiarrhythmic agents; therapy, blood levels, monitoring, 211
 - cardiac drugs; ventricular, therapy, review, 195
 - encainide hydrochloride; toxicity, product withdrawal, 897
 - morcizine; therapy, DUE criteria, 873
 - therapy; ventricular; pharmacists, monitoring, 210
 - Asians; psychotherapeutic agents; pharmacokinetics, vs. Caucasians, 467
- Aspirin**
- alone and with flurbiprofen; effects, platelet aggregation, 935
 - and propoxyphene; pain therapy, codeine allergies, 658
 - and thrombolytic agents; myocardial infarction therapy, 486
 - myocardial infarction; prophylaxis, angina pectoris, 825
 - osteoarthritis; therapy, geriatrics, ulcer history, 740
 - Asthma; therapy; pediatrics, 685
- Availability**, drugs, see Drugs, availability
- B**
- Barbiturates**; delirium; therapy, intensive-care units, 456
- Benzazepine hydrochloride**; marketing; FDA approvals, 739
- Benzodiazepines**
- alone and with haloperidol; delirium therapy, intensive-care units, 456
 - epilepsy; therapy, review, 335
 - panic disorders; therapy, 893
 - pharmacokinetics; Asians vs. Caucasians, 467
- Beractant**; comparison, alcohols, cetyl, combination, colfosciril palmitate, tyloxapol; therapeutic equivalence, 909
- Beverages**; vehicles; cholestyramine, colestipol administration, palatability, 138
- Bioavailability**, see Drugs, availability
- Blood derivatives**; albumin human; dosage predictions, parenteral supplements, pediatrics, 704
- Blood levels**
- acetaminophen; overdose, monitoring, 765
- albumin human; dosage predictions, pediatrics, 704
- antiarrhythmic agents; therapy, monitoring, 211
- benzodiazepines; Asians vs. Caucasians, 467
- cardiac drugs; ventricular arrhythmia therapy, 195
- digoxin; toxicity, digoxin immune Fab retreatment, immunogenicity, 823
- gentamicin; dosage, predictions, pharmacokinetics, 706
- glyburide; pharmacokinetics, effects, age, 532
- lead; succimer therapy, FDA restrictions, 942
- lithium; pharmacokinetics, methodology, models, 376
- mercury; poisoning, pediatrics, 213
- phenytoin; dosage calculations, black African and Indian children, 928; effects, ultrafiltration and freezing, 132; high, impaired metabolism, 711
- recaiam hydrochloride; pharmacokinetics, computer programs, MS-DOS vs. Macintosh, 206
- triazolam; interactions, ranitidine, 539
- valproic acid; availability, stability, emulsions, 382
- vancomycin; dosage guidelines, neonates, 129; half-life, hepatic and renal dysfunction, 297
- Bloodletting**; hemochromatosis; therapy, 775
- Book Reviews**, 80, 159, 239, 316, 649, 729, 905, 885, 970
- Biopharmaceutics and Clinical Pharmacokinetics**, Fourth Edition, 649
- Cancer Chemotherapy by Infusion**, Second Edition, 239
- Clinical Pharmacology of Psychotherapeutic Drugs**, Third Edition, 159
- Diseases of the Nose, Throat, Ear, Head, and Neck**, Fourteenth Edition, 729
- Drug Interactions & Updates**, 1991, 805
- Drug Safety in Pregnancy**, 650
- Drugs in Pregnancy and Lactation**, Third Edition, 316
- Field Drug Reference for Emergency Care Providers**, 80
- Goodman and Gilman's The Pharmacological Basis of Therapeutics**, Eighth edition, 317
- Handbook of Drug Therapy in Liver and Kidney Disease**, 885
- Handbook of Psychiatric Emergencies**, 730
- Infections in Intravenous Drug Abusers**, 805
- Manual of Clinical Microbiology**, Fifth Edition, 885
- Patient Compliance in Medical Practice and Clinical Trials**, 970
- Pharmacological Treatment of Endocrinopathies: Bone Disease, Kidney Stones and Related Disorders**, 890
- Poisoning and Drug Overdose**, 243
- Regional Antineoplastic Drug Delivery in the Management of Malignant Disease**, 976
- Books Received**, 246, 318, 482, 650, 806, 890, 976
- Botulinum toxin type A**; dystonia; therapy, 88
- Bristol Laboratories**; encainide hydrochloride; product withdrawal, toxicity, 897
- Bromocriptine**; restless legs; therapy, nocturnal, 427
- Bronchodilators**; cromolyn sodium; asthma therapy, pediatrics, 685
- C**
- Calcium antagonists**
- concomitant therapy, 630
 - heart failure; congestive, therapy, diastolic dysfunction, 850
 - proteinuria; therapy, diabetic nephropathies, 862
- Calcium regulators**; gallium nitrate; hypercalcemia therapy, FDA approvals, 573
- Calculations**; phenytoin; dosage, black African and Indian children, 928
- Cancer**, see Antineoplastic agents
- Cancer drugs**, see Antineoplastic agents
- Candidiasis**; fluconazole; therapy, DUE criteria, 222
- Captopril**
- concomitant therapy, 500
 - kidney diseases; therapy, 25
- Carbamazepine**
- epilepsy; therapy, review, 335
 - restless legs; therapy, nocturnal, 427
- Carcinoma**; interleukin 2; renal cell, single agent therapy, FDA denial, 141; renal cell, therapy, 110
- Cardiac drugs**
- angina pectoris; unstable, therapy, 825
 - antiarrhythmic agents; therapy, blood levels, monitoring, 211; therapy, monitoring, pharmacists, 210
 - arrhythmia; ventricular, therapy, review, 195
 - digoxin; toxicity, digoxin immune Fab retreatment, immunogenicity, 823
 - encainide hydrochloride; product withdrawal, toxicity, 897
 - morcizine; arrhythmia therapy, DUE criteria, 873
 - recaiam hydrochloride; pharmacokinetics, computer programs, MS-DOS vs. Macintosh, 206
- Carisoprodol**; muscle cramp; therapy, nocturnal leg cramps, 427
- Caucasians**; psychotherapeutic agents; pharmacokinetics, vs. Asians, 467
- Cefazidime**
- comparison, ciprofloxacin lactate; therapy, nosocomial pneumonia and urinary tract infections, 49
 - effects; amikacin-resistant isolates, in vitro, 544
- Cephalosporins**; cefazidime; susceptibility, amikacin-resistant isolates, in vitro, 544; vs. ciprofloxacin, pneumonia and urinary tract infections, therapy, 49
- Charcoal activated**; therapy; impaired phenytoin excretion, liver diseases, 711
- Chickenpox**; acyclovir; therapy, prophylaxis, HIV infections, 301
- Chloral hydrate**; interactions; furosemide, pediatrics, 385
- Cholestyramine**, see Cholestyramine resin
- Cholestyramine resin**
- hyperlipidemia; therapy, protocols, 943
 - palatability; oral formulations, vehicles, preferences, 138
- Choline**; Alzheimer's disease; therapy, mechanism of action, review, 447
- Ciprofloxacin**; effects; amikacin-resistant isolates, in vitro, 544
- Ciprofloxacin hydrochloride**; interactions; warfarin, PT effects, lack, 136
- Ciprofloxacin lactate**; comparison, cefazidime; therapy, nosocomial pneumonia and urinary tract infections, 49
- Classification**; steroids; anabolic, controlled substances, 417
- Clearance**, see Excretion
- Clindamycin phosphate**; concomitant therapy, 931
- Clinical Pharmacy**
- acknowledgment to reviewers—October 1, 1990, to September 30, 1991, 946
 - instructions for submitting computer disks with revised manuscripts, 62
 - procedure for submission of manuscripts to journals published by the American Society of Hospital Pharmacists, 60
- Clinical studies**
- meta-analysis; health data, applications and problems, 4
 - ondansetron hydrochloride; prophylaxis, antineoplastic toxicity, 430
- Codine**; allergies; alternative analgesics, 658
- Colestipol**; hyperlipidemia; therapy, protocols, 943
- Colestipol hydrochloride**; palatability; oral formulations, vehicles, preferences, 138
- Colfosciril palmitate**; combination, alcohols, cetyl, tyloxapol; vs. beractant, therapeutic equivalency, 909
- Colonic neoplasms**
- fluorouracil and levensole; combined therapy, review, 95
 - levamisole and fluorouracil; combined therapy, review, 95
- Colony-stimulating factors**
- filgrastim; DUE criteria, 950
 - neutropenia; therapy, HIV infections, review, 268
 - sargramostim; DUE criteria, 947
- Colorectal neoplasms**
- interleukin 2; therapy, 110
 - levamisole; therapy, review, 95
- Combined therapy**
- aspirin and thrombolytic agents; myocardial infarction, effects, mortality, 486
 - fluorouracil and levensole; colonic neoplasms, review, 95
 - levamisole and fluorouracil; colonic neoplasms, review, 95
 - thrombolytic agents and aspirin; myocardial infarction, effects, mortality, 486
- Commentary**, 943
- Compliance**; patients; deferoxamine therapy, hemochromatosis, 775
- Computers**; programs; MS-DOS vs. Macintosh, recaiam pharmacokinetics, 206; NONNEM, lithium pharmacokinetics, 376; warfarin dosage, predictions, vs. nomogram, 923
- Contraceptives, oral**; endometriosis; therapy, 518
- Contraindications**
- botulinum toxin type A, 88
 - drugs; lactation, 594
- Controlled substances**; steroids; anabolic, reclassification, 417
- Copper Cu 67**; radionuclides; monoclonal antibodies, neoplasms, 359
- Correction Notices**, 261, 429, 501, 824, 913
- Attention-deficit hyperactivity disorder (Aug 1990, Therapy Review)**, 261
- Criteria for use of ketorolac tromethamine in adult

inpatients and outpatients (Sep 1991, DUE Criteria), 913
 Current issues in the treatment of epilepsy (May 1991, Therapy Review), 501
 Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin (Feb 1991, Research Notes), 429
 Intravenous quinidine recommended for severe *Plasmodium falciparum* malaria; injectable quinine discontinued by CDC Drug Service (Sep 1991, News), 913
 Management of postoperative pain by continuous epidural infusion of analgesics (Oct 1991, Therapy Review), 824
 Olsalazine approved for use in ulcerative colitis (Dec 1990, News), 261
Costs
 deferoxamine mesylate; hemochromatosis therapy, 775
 filgrastim; prophylaxis, neutropenia, FDA approvals, 321
 interleukin 2: renal cell carcinoma, single agent therapy, FDA denial, 141
 pulmonary surfactants; respiratory distress syndrome therapy, 909
 sargramostim, 411
 thrombolytic agents; myocardial infarction therapy, 486
CP Continuing Education, 68, 147, 228, 309, 392, 474, 552, 638, 718, 792, 876, 953
Creatinine; clearance; gentamicin excretion, renal function estimation, 931; predictions, lithium pharmacokinetics, models, 376
Cromolyn sodium; asthma; therapy, pediatrics, 685
Current Literature, 74, 154, 235, 313, 397, 478, 558, 644, 726, 803, 880, 966
Cushing's syndrome; ketoconazole; therapy, mechanism of action, 12
Cytokines; *Mycobacterium avium* complex; therapy, AIDS, review, 280
Cytotoxic agents, see Antineoplastic agents

D

Danazol; endometriosis; therapy, 518
Deferoxamine mesylate; hemochromatosis; therapy, 775
Delirium; therapy; review, intensive-care units, 456
Desmopressin acetate; dosage; high, mechanism of action, antidiuretic effects, 912
Devices
 blood pressure; ambulatory care, monitoring, assessment, 175
 infusion pumps; terbutaline, preterm labor, home therapy, 292
 medical; latex, adverse reactions, FDA recommendations, 417
Diabetes mellitus; calcium antagonists; diabetic nephropathies, proteinuria therapy, 862
Diabetic nephropathies; calcium antagonists; proteinuria therapy, diabetes mellitus, 862
Digoxin; toxicity; therapy, digoxin immune Fab retreatment, immunogenicity, 823
Digoxin immune Fab; therapy; immunogenicity, retreatment, 823
Diltiazem
 angina pectoris; unstable, therapy, 825
 proteinuria; therapy, diabetic nephropathies, 862
Dimercaprol; antidotes; mercury poisoning, pediatrics, 213
Diuretics
 doxazosin mesylate; hypertension therapy, 9 furosemide; interactions, chloral hydrate, pediatrics, 385
 heart failure; congestive, therapy, diastolic dysfunction, 850
Dosage
 acyclovir; chickenpox, herpes zoster therapy, HIV infections, 301
 albumin human; predictions, equations, parenteral supplements, pediatrics, 704
 alfenatant hydrochloride; DUE criteria, 635
 analgesics; pain therapy, pediatrics, 667
 benazepril hydrochloride, 739
 charcoal activated; multiple dose therapy, phenytoin toxicity, liver diseases, 711
 desmopressin acetate; high, mechanism of action, antidiuretic effects, 912
 digoxin immune Fab, 823
 doxazosin mesylate; hypertension, therapy, 9
 enalapril maleate; DUE criteria, 63
 epoetin; DUE criteria, 143, 303

etodolac, 416
 fentanyl; transdermal patches, pain therapy, 9
 fentanyl citrate; DUE criteria, 635
 filgrastim, 321; neutropenia prophylaxis, chemotherapy, 787
 flucloxacillin; DUE criteria, 222
 fludarabine phosphate, 496
 gallium nitrate, 573
 gastrointestinal drugs; stress ulcer prophylaxis, DUE criteria, 787
 gentamicin; predictions, pharmacokinetics, methodology, 706
 heparin; thromboembolism therapy, guidelines, 503
 heparin; DUE criteria, 549
 interleukin 2; neoplasms therapy, 110
 isradipine, 573
 ketorolac tromethamine; DUE criteria, 715
 levamisole; colorectal neoplasms therapy, 95
 lorazepam; sedation, amnesia, pediatrics, 625
 midazolam hydrochloride; DUE criteria, 368
 misoprostol; DUE criteria, 307
 moricizine; arrhythmia therapy, DUE criteria, 873
 ondansetron hydrochloride, 249; DUE criteria, 471; review, 430
 overdose; acetaminophen, acetylcysteine therapy, 765
 phenytoin; calculations, black African and Indian children, 928
 psychotherapeutic agents; Asians vs. Caucasians, 467
 pulmonary surfactants; respiratory distress syndrome therapy, 909
 radiopharmaceuticals; monoclonal antibodies, neoplastics, 359
 ramipril, 573
 sargramostim, 411; DUE criteria, 947
 skeletal muscle relaxants; mechanically ventilated patients, 32
 succimer; lead poisoning, therapy, 914
 sufentanil citrate; DUE criteria, 635
 terbutaline sulfate; preterm labor, home infusion therapy, 292
 vancomycin; guidelines, neonates, 129
 vancomycin hydrochloride; hepatic and renal dysfunction, 297
 warfarin; predictions, nomograms vs. computers, 923; thromboembolism therapy, guidelines, 503
Dosage forms
 etodolac, 416
 filgrastim, 321
 ondansetron hydrochloride, 249
 sargramostim, 411

Dosage schedules
 acetylcysteine; therapy, acetaminophen overdose, 765
 analgesics; continuous epidural infusions, postoperative pain, 745
 anticonvulsants; epilepsy therapy, long term, 335
 aspirin and flurbiprofen; platelet aggregation effects, 935
 flurbiprofen and aspirin; platelet aggregation effects, 935
 interleukin 2; renal cell carcinoma, single agent therapy, FDA denial, 141

Doxazosin mesylate; hypertension; therapy, FDA approvals, 9

Drug administration
 cholestyramine resin; beverages, palatability, 138
 colestipol hydrochloride; beverages, palatability, 138
 self-medication; terbutaline infusion, preterm labor therapy, 292

succimer; lead poisoning, therapy, 914

thrombolytic agents; comparisons, myocardial infarction therapy, 486

Drug administration rate; injections; continuous vs. intermittent infusion, toxicity, 630

Drug administration routes
 asthma; acute vs. prophylactic therapy, pediatrics, 685

Deferoxamine mesylate; s.c., i.v., hemochromatosis therapy, 775

epidural; analgesics, continuous epidural infusions, postoperative pain, 745

pentamidine isethionate; infusions, adverse reactions, facial numbness, 257
 terbutaline sulfate; subcutaneous infusion, preterm labor therapy, 292
 triazolam; oral vs. i.v., interactions, ranitidine, pharmacokinetics, 539

Drug administration sites; intravenous; toxicity, extravasation, phlebitis, 630

Drug interactions

chloral hydrate and furosemide; pediatrics, 385
 ciprofloxacin hydrochloride and warfarin; PT effects, lack, 136
 flucloxacillin; review, 179
 flurbiprofen and aspirin; effects, platelet aggregation,

lack, 935
 furosemide and chloral hydrate; pediatrics, 385
 ibuprofen and misoprostol or ranitidine hydrochloride; lack, 870
 misoprostol and ibuprofen; lack, 870
 ranitidine hydrochloride and ibuprofen; lack, 870
 ranitidine hydrochloride and triazolam; pharmacokinetics, 539
 triazolam and ranitidine hydrochloride; pharmacokinetics, 539
 warfarin and ciprofloxacin hydrochloride; PT effects, lack, 136
Drugs interactions therapy; aspirin and flurbiprofen; effects, platelet aggregation, lack, 935
Drug Reaction Alerts, 74, 154, 235, 313, 397, 478, 558, 644, 726, 803, 880, 966
Drugs, adverse reactions
 codeine; allergies, alternative analgesics, 658
 latex; allergies, FDA recommendations, 417
 pentamidine isethionate; facial numbness, infusions, 257
 vaccines; Vaccine Adverse Event Reporting System, 9

Drugs, availability
 triazolam; interactions, ranitidine, 539
 valproate sodium; syrups, vs. valproic acid emulsions, 382
 valproic acid; emulsions, vs. valproate sodium syrup, 382

Drugs, body distribution
 aminoglycosides; AIDS, 784
 glyburide; effects, age, 532
 lithium; pharmacokinetics, methodology, models, 376

Drugs, clinical effectiveness
 antiarrhythmic agents; therapy, blood levels, monitoring, 211
 drugs; nonprescription; lack, product withdrawal, FDA list, 88
 meta-analysis; methodology, applications and problems, 4
 thrombolytic agents; myocardial infarction therapy, 486

Drugs, nonprescription; product withdrawal; ingredients, FDA list, 88

Drug use
 evaluation; filgrastim, neutropenia prophylaxis, criteria, 787; gastrointestinal drugs, stress ulcer prophylaxis, criteria, 787; ketorolac, criteria, 715; moricizine, criteria, 873; sargramostim, criteria, 947
 review; alfentanil, fentanyl, sufentanil, criteria, quality assurance programs, 635; enalapril, criteria, quality assurance programs, 635; epoetin, criteria, quality assurance programs, 635; fentanyl, criteria, quality assurance programs, 222; heparin, criteria, quality assurance programs, 635; midazolam, criteria, quality assurance programs, 388; misoprostol, criteria, quality assurance programs, 307; ondansetron, criteria, quality assurance programs, 471

DUE Criteria, 63, 143, 222, 303, 388, 471, 549, 635, 715, 787, 873, 947

enalapril maleate, 63
 epoetin, 143, 303

fentanyl citrate, sufentanil citrate, and alfentanil hydrochloride, 635

filgrastim, 950
 flucloxacillin, 222

hetastarch, 549
 ketorolac tromethamine, 715
 midazolam hydrochloride, 388

misoprostol, 307
 moricizine, 873
 ondansetron hydrochloride, 471

sargramostim, 947
 stress ulcer prophylaxis in intensive-care patients, 787

Dystonia; botulinum toxin type A; therapy, 88

E

Edetate calcium disodium; therapy; mercury poisoning, 742

Editorials, 141, 210, 942
 Antiarrhythmic monitoring; misplaced emphasis, 211

Recombinant interleukin-2 and the quest for FDA approval, 141

Succimer; controversial issues involving the release of a new product, 942

Trials and tribulations of evaluating ventricular arrhythmias, 210

Education
 acquired immunodeficiency syndrome; therapy, re-

search, AIDS conference, 809
panic disorders; awareness, therapy, 893
Elimination, see **Metabolism**
Emulsions; valproic acid; stability, availability, vs. valproate sodium syrup, 382
Enalapril maleate
kidney diseases; therapy, 25
use; review, criteria, quality assurance programs, 63
Encainide hydrochloride; product withdrawal; toxicity, 897
Endometriosis; therapy, 518
Enterobacter cloacae; resistance; ceftazidime, pneumonia, 49
Enzymes; alglucerase; replacement therapy, Gaucher's disease, FDA approvals, 496
Epilepsy; therapy; review, 335
Epoetin; use; review, criteria, quality assurance programs, 143, 303
Equations
albumin human; dosage, predictions, pediatrics, 704
phenytoin; dosage, pediatrics, pharmacogenetics, 928
Equivalence
valproate sodium; syrups, availability, vs. valproic acid emulsions, 382
valproic acid; emulsions, availability, vs. valproate sodium syrup, 382
Equivalency, generic; thioridazine hydrochloride; brands, comparison, efficacy, quality of life, 938
Equivalency, therapeutic; pulmonary surfactants; comparison, respiratory distress syndrome therapy, 909
Ethnic groups; Hispanic Americans; psychotherapeutic agents, pharmacogenetics, 467
Ethosuximide; epilepsy; therapy, review, 335
Etodolac; marketing; FDA approvals, osteoarthritis therapy, 416
Excretion
aminoglycosides; AIDS, 784
benzodiazepines; clearance, Asians vs. Caucasians, 467
drugs; lactation, review, 594
gentamicin; renal function estimation, 931
glyburide; effects, age, 532
lithium; clearance, methodology, models, 376
phenytoin sodium; impaired, liver diseases, activated charcoal therapy, 711
vancomycin; hepatic and renal dysfunction, 297
Extravasation; injections; i.v. infusion sites, toxicity, 630

F

Fentanyl
patches transdermal; pain therapy, FDA approvals, 9
pharmacology; clinical uses, review, 581
Fentanyl citrate; use; review, criteria, quality assurance programs, 635
Filgrastim
approvals; FDA, prophylaxis, neutropenia, chemotherapy, 321
use; evaluation, neutropenia prophylaxis, criteria, 950
Filters; ultra; products, effects, phenytoin blood levels, 132
Filtration; ultra; methods, phenytoin blood levels, 132
Fluconazole
pharmacology; review, 179
use; review, criteria, quality assurance programs, 222
Fludarabine phosphate; marketing; FDA approvals, 496
Fluorouracil; and levamisole; colonic neoplasms, combined therapy, 95
Flurbiprofen; alone and with aspirin; effects, platelet aggregation, 935
Food and Drug Administration (U.S.)
approvals; alglucerase marketing, 496; benazepril marketing, 739; doxazosin, hypertension therapy, 9; etodolac marketing, 416; fentanyl, transdermal patches, marketing, pain therapy, 9; filgrastim marketing, 321; fludarabine marketing, 496; gallium marketing, 573; isradipine, ramipril, marketing, 573; ondansetron, 249; sargamostim marketing, 411; succimer marketing, controversies, 942
drugs, nonprescription; ingredients, product withdrawal, list, 88
interleukin 2; renal cell carcinoma, single agent therapy, FDA denial, 141
latex; medical devices, allergies, recommendations, 417
Formulations
cholestyramine resin; oral, palatability, vehicles, 138
colestipol hydrochloride; oral, palatability, vehicles, 138
Freezing; effects; phenytoin blood levels, ultrafiltration methods, 132

G

Gallium nitrate; marketing; FDA approvals, 573
Gastrointestinal drugs
glutamic acid hydrochloride; effects, gastric pH, 866
histamine H₂ antagonists; use, evaluation, stress ulcer prophylaxis, criteria, 787
misoprostol; DUE criteria, quality assurance programs, 307; interactions, ibuprofen, lack, 870
ranitidine; peptic ulcers, prophylaxis, osteoarthritis, geriatrics, 740
ranitidine hydrochloride; interactions, ibuprofen, lack, 870; interactions, triazolam, pharmacokinetics, 539
scleroderma; systemic, therapy, 14
sucralfate; stress ulcer prophylaxis, DUE criteria, 787
Gaucher's disease; alglucerase; therapy, FDA approvals, 496
Gentamicin
dosage; predictions, pharmacokinetics, methodology, 706
excretion; renal function estimation, 931
Geriatrics; osteoarthritis; therapy, ulcer history, 740
Globulin immune; neutropenia; therapy, HIV infections, review, 268
Glutamic acid hydrochloride; effects; gastric pH, 866
Glyburide; pharmacokinetics; effects, age, 532
Goserelin agonists; nafoxalin; endometriosis therapy, 518
Guidelines, treatment, see **Protocols**

H

Half-life
aminoglycosides; AIDS, 784
vancomycin; blood levels, hepatic and renal dysfunction, 297
Haloperidol; alone and with benzodiazepines; delirium therapy, intensive-care units, 456
Health-benefit programs; reimbursement; meta-analysis, 4
Health care; home; terbutaline infusion, preterm labor therapy, 292
Health professions; latex; medical devices, allergies, FDA recommendations, 417
Heavy metal antagonists
N-acetyl-D,L-penicillamine; mercury poisoning, pediatrics, 213
deferoxamine mesylate; hemochromatosis therapy, 775
dimeracrol; mercury poisoning, pediatrics, 213
edetate calcium disodium; therapy, mercury poisoning, 742
penicillamine; hepatolenticular degeneration therapy, 839
succimer; FDA approvals, controversies, 942; lead poisoning, therapy, 914
trientine; hepatolenticular degeneration therapy, 839
zinc; hepatolenticular degeneration, maintenance therapy, 839
Hemochromatosis; therapy, 775
Hemophilia; pentamidine; toxicity, pancreatitis, AIDS, 56
Heparin
injections; i.v. infusion sites, toxicity, 630
myocardial infarction; prophylaxis, angina pectoris, 825
thromboembolism; therapy, guidelines, 503
Hepatolenticular degeneration; heavy metal antagonists; therapy, 839
Herpes zoster; acyclovir; therapy, prophylaxis, HIV infections, 301
Hetastarch; use; review, criteria, quality assurance programs, 549
History; skeletal muscle relaxants; review, developments, 32
HIV infections
acyclovir; chickenpox, herpes zoster therapy, HIV infections, 301
therapy; neutropenia, review, 268; research, AIDS conference, 809
Hodgkin's disease; sargamostim; therapy, FDA approvals, 411
Hospitals; intensive-care units; delirium therapy, review, 456; patients, stress ulcer prophylaxis, DUE criteria, 787
Hyperalimentation, see **Nutrition; parenteral**

Hypercalcemia; gallium nitrate; therapy, cancer-related, FDA approvals, 573
Hyperlipidemia; therapy; protocols, National Cholesterol Education Program, 943
Hypertension
benazepril hydrochloride; therapy, FDA approvals, 739
calcium antagonists; therapy, diabetic nephropathies, 862
doxazosin mesylate; therapy, FDA approvals, 9
enalapril maleate; DUE criteria, 63
isradipine; therapy, FDA approvals, 573
labetalol hydrochloride; therapy, pediatrics, 500
ramipril; therapy, FDA approvals, 573
therapy; ambulatory care, monitoring, assessment, 175
Hyperthyroidism; mercury; toxicity, poisoning, 742
Hypotensive agents
benazepril hydrochloride; FDA approvals, 739
doxazosin mesylate; therapy, FDA approvals, 9
enalapril maleate; DUE criteria, quality assurance programs, 63
isradipine; FDA approvals, 573
labetalol hydrochloride; therapy, pediatrics, 500
ramipril; FDA approvals, 573

I

Iatrogenic diseases, see **Drugs, adverse reactions**
Ibuprofen
interactions; misoprostol, ranitidine, lack, 870
osteoarthritis; therapy, geriatrics, ulcer history, 740
Imipenem; effects; amikacin-resistant isolates, in vitro, 544
Immunogenicity; digoxin immune Fab; retreatment, digoxin toxicity, 823
Immunosuppressive agents; scleroderma; systemic, therapy, 14
Immunotherapy
colony-stimulating factors; neutropenia, HIV infections, review, 268
filgrastim; neutropenia prophylaxis, chemotherapy, DUE criteria, 950; prophylaxis, neutropenia, FDA approvals, 321
globulin immune; neutropenia, HIV infections, review, 268
interleukin 2; neoplasms therapy, 110
radiionuclides; monoclonal antibodies, neoplasms, 359
sargamostim; DUE criteria, 947; FDA approvals, 411
Incompatibilities; ondansetron hydrochloride; review, 430
Infections; therapy; opportunistic, research, AIDS conference, 809
Infusion devices, see **Devices; infusion pumps**
Injections
analgesics; continuous epidural infusions, postoperative pain, 745
botulinum toxin type A; dystonia therapy, 88
furosemide; interactions, chloral hydrate, pediatrics, 385
gallium nitrate; hypercalcemia therapy, FDA approvals, 573
intravenous; toxicity, extravasation, phlebitis, 630
pentamidine isethionate; infusions, adverse reactions, facial numbness, 257
terbutaline sulfate; subcutaneous infusion, preterm labor therapy, 292
Interleukin 2
approvals; renal cell carcinoma, single agent therapy, FDA denial, 141
neoplasms; therapy, review, 110
Iodine I 125; radionuclides; monoclonal antibodies, neoplasms, 359
Iodine I 131; radionuclides; monoclonal antibodies, neoplasms, 359
Isradipine; marketing; FDA approvals, 573

K

Ketoconazole; Cushing's syndrome; therapy, mechanism of action, 12
Ketorolac tromethamine; use; evaluation, criteria, 715
Kidney diseases; angiotensin-converting enzyme inhibitors; therapy, 25
Kidney failure; vancomycin hydrochloride; chronic, blood levels, half-life, 297
Klebsiella pneumoniae; resistance; ciprofloxacin, pneumonia, 49

L

Labetalol hydrochloride; hypertension; therapy, pediatrics, 500
Labor; terbutaline sulfate; preterm, home infusion therapy, 292
Lactation; drugs; patient information, excretion, review, 594
Latex; adverse reactions; allergies, FDA recommendations, 417
Laws; Anabolic Steroids Act of 1990; reclassification, controlled substances, 417
Lead; poisoning; succimer therapy, 914; succimer therapy, FDA approvals, controversies, 942
Lechin; Alzheimer's disease; therapy, mechanism of action, review, 447
Letters, 177, 257, 333, 429, 500, 664, 742, 823, 912
 Antimicrobial dosages in guidelines for prevention of bacterial endocarditis, 501
 Correction to *AHFS Drug Information*, 91, 913
 Cryoprecipitate for uremic bleeding, 429
 Dosage of antimycobacterial agents, 664
 Ethnicity and clozapine-induced agranulocytosis, 743
 Hyperthyroidism associated with mercury poisoning, 742
 Interferon for genital warts, 177
 Inverse relationship between desmopressin dosage and antidiuretics, 912
 Labetalol for treatment of hypertension in a child, 500
 Laboratory monitoring of heparin therapy, 824
 Pentamidine-induced facial numbness, 257
 Retreatment with digoxin immune Fab, 823
 Valproic acid hepatotoxicity in adults and older children, 665
 Verapamil and left ventricular hypertrophy, 333
Leukemia
 fludarabine phosphate; B-cell, chronic, therapy, FDA approvals, 496
 sargramostim; lymphocytic, acute, therapy, FDA approvals, 411
Levamisole; colorectal neoplasms; therapy, review, 95
Lisinopril; kidney diseases; therapy, 25
Lithium; neutropenia; therapy, HIV infections, review, 268
Lithium carbonate; pharmacokinetics; methodology, models, 376
Liver cirrhosis; vancomycin hydrochloride; blood levels, half-life, 297
Liver diseases; phenytoin sodium; impaired metabolism, activated charcoal therapy, 711
Lorazepam; dosage; sedation, amnesia, pediatrics, 625
Lymphoma
 radionuclides; monoclonal antibodies, 359
 sargramostim; non-Hodgkin's, therapy, FDA approvals, 411

M

Magnesium sulfate; concomitant therapy, 292
Manufacturing; valproic acid; emulsions, availability, fresh vs. stored, 382
Marketing
 alglucerase; FDA approvals, 496
 benazepril hydrochloride; FDA approvals, 739
 doxazosin mesylate; hypertension therapy, FDA approvals, 9
 encainide hydrochloride; product withdrawal, toxicity, 897
 etodolac; osteoarthritis therapy, FDA approvals, 416
 fentanyl; transdermal patches, FDA approvals, pain therapy, 9
 filgrastim; prophylaxis, neutropenia, FDA approvals, 321
 fludarabine phosphate; FDA approvals, 496
 gallium nitrate; FDA approvals, 573
 isradipine; FDA approvals, 573
 ondansetron hydrochloride; prophylaxis, chemotherapy toxicity, FDA approvals, 249
 product withdrawal; nonprescription drugs, FDA list, 88
 ramipril; FDA approvals, 573
 sargramostim; FDA approvals, 411
 succimer; FDA approvals, controversies, 942
Mechanism of action
 acetylcholinesterase inhibitors; Alzheimer's disease therapy, review, 447
 amino acids; Alzheimer's disease therapy, review, 447
 analgesics; continuous epidural infusions, postoperative pain, 745; pain therapy, pediatrics, 667
 calcium antagonists; proteinuria therapy, diabetic nephropathies, 862

desmopressin acetate; high dose, antidiuretic effects, 912
 ketoconazole; Cushing's syndrome therapy, 12
 parasympathomimetic agents; Alzheimer's disease therapy, review, 447
Melanoma; interleukin 2; therapy, 110
Memory disorders; therapy; Alzheimer's disease, review, 447
Menigitis; fluconazole; cryptococcal, therapy, DUE criteria, 222

Mercury
 poisoning; dimercaptoproline, N-acetyl-D,L-penicillamine, antidotes, pediatrics, 213; toxicity, hyperthyroidism, 742

Metabolism
 acetaminophen; acetaminophen metabolites, toxicity, 765
 phenytoin sodium; impaired, liver diseases, activated charcoal therapy, 711
Metals; mercury; poisoning, hyperthyroidism toxicity, 742; poisoning, pediatrics, 213

Methodology
 albumin human; dosage predictions, parenteral supplements, pediatrics, 704
 antiarrhythmic agents; therapy, blood levels, monitoring, 211
 cardiac drugs; monitoring, ventricular arrhythmia therapy, 195
 creatinine; clearance, gentamicin excretion, renal function estimation, 931
 gentamicin; dosage predictions, pharmacokinetics, 706
 lithium carbonate; pharmacokinetics, models, 376
 meta-analysis; health data, applications and problems, 4
 pharmacokinetics; computer programs, MS-DOS vs. Macintosh, 206

phenytoin; dosage, pediatrics, pharmacogenetics, 928
 warfarin; dosage predictions, nomograms vs. computers, 923

Midazolam hydrochloride; use; review, criteria, quality assurance programs, 388

Misoprostol
 interactions; ibuprofen, lack, 870
 use; review, criteria, quality assurance programs, 307

Models; pharmacokinetics; recainam, computer programs, MS-DOS vs. Macintosh, 206

Monoamine oxidase inhibitors; panic disorders; therapy, 893

Moricizine; use; evaluation, arrhythmia therapy, criteria, 873

Mortality; myocardial infarction; effects, thrombolytic agents and aspirin, 486

Muscle cramp; therapy; nocturnal leg cramps, 427

Mycobacterium avium complex; therapy; AIDS, review, 280

Myocardial infarction
 aspirin and thrombolytic agents; comparisons, therapy, 486

thrombolytic agents; comparisons, therapy, 486

N

Nafarelin; endometriosis; therapy, 518
National Cholesterol Education Program; protocols; hyperlipidemia therapy, 943

Nausea; ondansetron hydrochloride; therapy, DUE criteria, 471

Negroes; psychotherapeutic agents; pharmacogenetics, 467

Neoplasms
 radionuclides; monoclonal antibodies, 359

therapy; research, AIDS conference, 809

Neutropenia
 filgrastim; prophylaxis, chemotherapy, FDA approvals, 321

therapy; HIV infections, review, 268

News, 4, 88, 167, 249, 321, 411, 486, 569, 653, 733, 809, 893

American Academy of Pediatrics issues recommendations on treatment of Lyme disease, 738

Anabolic steroids reclassified as Schedule III controlled substances, 417

Benzephril approved for treatment of hypertension, 739

Bristol discontinues sales of encainide, 897

CAST II halted because of mortality trends, 897

CDC offers recommendations for folic acid prevention of neural tube defects, 898

CDC publishes guidelines for energy testing in HIV-infected persons, 653

CDC revises melofloquine dosage recommendations, 417

Changes in federal programs for reporting suspected adverse reactions to vaccines announced, 9

Conference attendees told ISIS-3 shows equal efficacy, safety differences among thrombolytics, 486
 Consensus panel considers uses of botulinum toxin, 88

Consensus panel stresses need for greater awareness of panic disorder and its treatment, 893
 Consensus report focuses on hypertension during pregnancy, 93

Doxazosin approved as antihypertensive agent, 9
 E5 antitoxin antibody reduces mortality among subset of patients with gram-negative sepsis, study finds, 897

Enzyme replacement therapy approved for Gaucher's disease, 496

Etdolac approved for marketing in the United States, 416

FDA advisory committee reviews data suggesting ethnic differences in response to zidovudine, recommends no changes in drug use, 326
 FDA bars 223 ingredients in nonprescription drug products, 88

Fludarabine approved for marketing, 496
 Gallium marketed for treatment of cancer-related hypercalcemia, 573

Guidelines for *Pneumocystis carinii* pneumonia prophylaxis in children issued, 569

Haemophilus b immunization recommendations updated by American Academy of Pediatrics, 733
 Highlights of the Seventh International Conference on AIDS, 809

Intravenous quinidine recommended for severe *Plasmodium falciparum* malaria; injectable quinine discontinued by CDC Drug Service, 653

Latex in medical devices may cause severe reactions; extra care advised, 417

Marketing of recombinant granulocyte-macrophage colony-stimulating factor approved by FDA, 411

New method of analyzing health data still debate, 4

New recommendations for prevention of bacterial endocarditis include amoxicillin use, 168

News Briefs, 10, 94, 176, 253, 326, 417, 498, 573, 657, 739, 822, 898

Ondansetron granted marketing approval, 249

Recombinant granulocyte colony-stimulating factor approved by FDA, 321

Report assesses use of blood pressure monitoring device for ambulatory patients, 175

Report on pain management in childhood cancer published, 93

Rubella prevention guidelines updated by CDC, 249

Single large dose of intravenous immune globulin more effective than four-day regimen in patients with Kawasaki disease, investigators report, 657

Study raises safety questions about β-agonist inhaler overuse, 822

Study shows effect of postmenopausal estrogen therapy on cardiovascular risk, 897

Study shows efficacy of monoclonal antibody in patients with sepsis and gram-negative bacteremia, 321

Transdermal fentanyl approved for chronic pain management, 9

Two cardiovascular agents, ramipril and isradipine, approved for U.S. market, 573

Two reports on hypertension available from National Heart, Lung, and Blood Institute, 253

Upcoming Specialty Meetings, 11, 94, 175, 326, 498, 574, 657, 739, 822, 898

Year-end review shows 23 new drugs approved, 14 important biologic licensing actions taken by FDA, 167

Niacin; hyperlipidemia; therapy, protocols, 943

Nicardipine; proteinuria; therapy, diabetic nephropathy, 862

Nicotinic acid, see Niacin

Nifedipine; angina pectoris; unstable, therapy, 825

Nitroglycerin; angina pectoris; unstable, therapy, 825

Nomograms; warfarin; dosage, predictions, vs. computers, 923

Nutrition; parenteral; albumin human, dosage predictions, pediatrics, 704

O

Ofoxacin; effects; amikacin-resistant isolates, in vitro, 544

Ondansetron hydrochloride

approvals; prophylaxis, chemotherapy toxicity, 249

pharmacology; review, 430

use; review, criteria, quality assurance programs, 471

Opiates

delirium; therapy, intensive-care units, 456
pain; postoperative, continuous epidural infusions, 745; therapy, pediatrics, 667
Osteoarthritis
etodolac; therapy, FDA approvals, 416
therapy; geriatrics, ulcer history, 740

P**Pain**

analgesics; postoperative, continuous epidural infusions, 745
fentanyl; transdermal patches, therapy, FDA approvals, 9
ketorolac tromethamine; therapy, DUE criteria, 715
therapy; acute, pediatrics, 667
Pancreatitis; pentamidine; toxicity, AIDS, hemophilia, 56
Panic disorders; therapy, 893
Paralysis; skeletal muscle relaxants; mechanically ventilated patients, 32
Parasympatholytic agents; asthma; therapy, pediatrics, 685
Parasympathomimetic agents; Alzheimer's disease; therapy, mechanism of action, review, 447
Parenterals, see Injections
Patches transdermal; fentanyl; pain therapy, FDA approvals, 9
Patient education; hypertension; ambulatory care, monitoring, devices, 175
Patients
inpatients; gastrointestinal drugs, DUE criteria, 787; moricizine, DUE criteria, 873
latex; medical devices, allergies, FDA recommendations, 417
outpatients; fluconazole, DUE criteria, 222; ketorolac, DUE criteria, 715; moricizine, DUE criteria, 873; ondansetron therapy, DUE criteria, 471

Pediatrics

albumin human; dosage predictions, parenteral supplements, 704
analgesics; pain therapy, 667
asthma; therapy, 685
chloral hydrate; interactions, furosemide, 385
fluconazole; DUE criteria, 222
furosemide; interactions, chloral hydrate, 385
ketorolac tromethamine; DUE criteria, 715
labetalol hydrochloride; hypertension therapy, 500
lactation; drugs, excretion, review, 594
lorazepam; dosage, sedation, amnesia, 625
mercury; poisoning, 213
neonates; pulmonary surfactants, therapeutic equivalence, 909
ondansetron hydrochloride; therapy, DUE criteria, 471
phenytoin; dosage calculations, black African and Indian children, 928
succimer; therapy, FDA approvals, 942
vancomycin; neonates, dosage guidelines, 129
Penicillamine; hepatoenteric degeneration; therapy, 839
Pentamidine; toxicity; pancreatitis, AIDS, hemophilia, 56
Pentamidine isethionate; adverse reactions; facial numbness, infusions, 257
Pharmacists
antiarrhythmic agents; therapy, blood levels, monitoring, 211
arrhythmia; ventricular, therapy, monitoring, 210
Pharmacodynamics; glyburide; effects, age, 532
Pharmacogenetics
phenytoin; dosage calculations, pediatrics, 928
psychotherapeutic agents; race, ethnic groups, 467
Pharmacokinetics
alfentanil; review, 581
aminoglycosides; AIDS, 784
analgesics; continuous epidural infusions, postoperative pain, 745; pain therapy, pediatrics, 667
benazepril hydrochloride, 739
doxazosin mesylate; hypertension therapy, 9
drugs; lactation, excretion, review, 594
etodolac, 416
fentanyl; and derivatives, review, 581; transdermal patches, pain therapy, 9
filgrastim, 321
fluconazole; review, 179
fludarabine phosphate, 496
gallium nitrate, 573
gentamicin; dosage predictions, methodology, 706
glyburide; effects, age, 532
ibuprofen; interactions, misoprostol, ranitidine, lack, 870

interleukin 2; review, 110
isradipine, 573
levamisole; review, 95
lithium carbonate; methodology, models, 376
ondansetron hydrochloride, 249; review, 430
phenytoin; dosage calculations, pediatrics, 928
phenytoin sodium; impaired metabolism, excretion, liver diseases, 711

psychotherapeutic agents; race, ethnic groups, 467
ramipril, 573
recaimac hydrochloride; computer programs, MS-DOS vs. Macintosh, 206
sargramostim, 411
skeletal muscle relaxants; review, mechanically ventilated patients, 32
succimer; lead poisoning, therapy, 914
sufentanil; review, 581
triazolam; interactions, ranitidine, 539
valproate sodium; syrups, availability, vs. valproic acid emulsions, 382
valproic acid; emulsions, availability, vs. valproate sodium syrup, 382
vancomycin hydrochloride; relation, creatinine clearance, 297

Pharmacy, institutional, hospital

quality assurance; programs, alfentanil, fentanyl, sufentanil, DUE criteria, 635; programs, enalapril, DUE criteria, 63; programs, erythropoietin, DUE criteria, 143, 303; programs, filgrastim, neutropenia prophylaxis, DUE criteria, 950; programs, fluconazole, DUE criteria, 222; programs, hetastarch, DUE criteria, 549; programs, ketorolac, DUE criteria, 715; programs, midazolam, DUE criteria, 388; programs, misoprostol, DUE criteria, 307; programs, moricizine, arrhythmia therapy, DUE criteria, 873; programs, ondansetron, DUE criteria, 471; programs, sargamostim, DUE criteria, 947; programs, stress ulcer prophylaxis, DUE criteria, 787
Phenobarbital; epilepsy; therapy, review, 335

Phenytoin

blood levels; effects, ultrafiltration and freezing, 132
dosage; calculations, black African and Indian children, 928
epilepsy; therapy, review, 335
Phenytoin sodium; excretion; impaired, liver diseases, activated charcoal therapy, 711
phlebitis; infections; i.v. infusion sites, toxicity, 630
Physostigmine; Alzheimer's disease; therapy, mechanism of action, review, 447
Pituitary hormones; desmopressin acetate; high dose, mechanism of action, antidiuretic effects, 912
Platelet aggregation inhibitors
aspirin; alone and with flurbiprofen, effects, 935
flurbiprofen; alone and with aspirin, effects, 935
Pneumonia
ceftazidime, comparison, ciprofloxacin lactate; nosocomial, therapy, 49
ciprofloxacin lactate, comparison, ceftazidime; nosocomial, therapy, 49
Poisoning
acetaminophen; overdose, acetylcysteine therapy, 765
lead; succimer therapy, 914; succimer therapy, FDA approvals, controversies, 942
mercury; dimercaprol, N-acetyl-D,L-penicillamine, antidotes, pediatrics, 213; toxicity, hyperthyroidism, 742
Platelet aggregation inhibitors
aspirin; alone and with flurbiprofen, effects, 935
flurbiprofen; alone and with aspirin, effects, 935
Pneumonia
ceftazidime, comparison, ciprofloxacin lactate; nosocomial, therapy, 49
ciprofloxacin lactate; vs. ceftazidime, pneumonia and urinary tract infections therapy, 49
Mycobacterium avium complex; therapy, AIDS, review, 280
ofloxacin; susceptibility, amikacin-resistant isolates, in vitro, 544

hetastarch; DUE criteria, 549
hyperlipidemia; therapy, National Cholesterol Education Program, 943

ketorolac tromethamine; DUE criteria, 715
midazolam hydrochloride; DUE criteria, 388
misoprostol; DUE criteria, 307
moricizine; arrhythmia therapy, DUE criteria, 873
ondansetron hydrochloride; DUE criteria, 471
sargamostim; DUE criteria, 947
sufentanil citrate; DUE criteria, 635
vancomycin; dosage, neonates, 129
warfarin; thromboembolism therapy, 503

Psychotherapeutic agents

haloperidol; delirium therapy, intensive-care units, 456
pharmacokinetics; race, ethnic groups, 467
Pulmonary surfactants
alcohols, cetyl, combination, colfosciril palmitate, tyloxapol; vs. beractant, therapeutic equivalency, 909
beractant; vs. cetyl alcohol-colfosciril-tyloxapol, therapeutic equivalency, 909

Q**Quality assurance**

hospital pharmacy; programs, alfentanil, fentanyl, sufentanil, DUE criteria, 635; programs, enalapril, DUE criteria, 63; programs, erythropoietin, DUE criteria, 143, 303; programs, filgrastim, neutropenia prophylaxis, DUE criteria, 950; programs, fluconazole, DUE criteria, 222; programs, hetastarch, DUE criteria, 549; programs, ketorolac, DUE criteria, 715; programs, midazolam, DUE criteria, 388; programs, misoprostol, DUE criteria, 307; programs, moricizine, arrhythmia therapy, DUE criteria, 873; programs, ondansetron, DUE criteria, 471; programs, sargamostim, DUE criteria, 947; programs, stress ulcer prophylaxis, DUE criteria, 787

Quality of life; thiordiazine hydrochloride; generic equivalency, brands, comparison, 938

Quinidine; concomitant therapy, 823

Quinolones

ciprofloxacin; susceptibility, amikacin-resistant isolates, in vitro, 544
ciprofloxacin hydrochloride; interactions, warfarin, PT effects, lack, 136
ciprofloxacin lactate; vs. ceftazidime, pneumonia and urinary tract infections therapy, 49
Mycobacterium avium complex; therapy, AIDS, review, 280
ofloxacin; susceptibility, amikacin-resistant isolates, in vitro, 544

R**Race**

patients; psychotherapeutic agents, pharmacogenetics, 467
pediatrics; phenytoin dosage calculations, 928

Radionuclides; neoplasms; monoclonal antibodies, 359

Radiopharmaceuticals; neoplasms; monoclonal antibodies, 359

Ramipril; marketing; FDA approvals, 573

Ranitidine; ulcers; peptic, prophylaxis, osteoarthritis therapy, geriatrics, 740

Ranitidine hydrochloride; interactions; ibuprofen, lack, 870; triazolam, pharmacokinetics, 539

Rational therapy

cardiac drugs; ventricular arrhythmia therapy, 195
pharmacists; ventricular arrhythmia, monitoring, 210

Recalcaine hydrochloride; pharmacokinetics; computer programs, MS-DOS vs. Macintosh, 206

Reference books; lactation; drugs, patient information, review, 594

Regulations

Food and Drug Administration; nonprescription ingredients, withdrawal, 88
succimer; therapy, FDA restrictions, 942

Replacement solutions; hetastarch; DUE criteria, quality assurance programs, 549

Reports

botulinum toxin type A; dystonia therapy, 88
drugs, adverse reactions; and toxicity, Vaccine Adverse Event Reporting System, 9

Hypertension; monitoring, devices, assessment, 175

Research
acquired immunodeficiency syndrome; therapy, AIDS conference, 809

hypertension; monitoring, devices, assessment, 175

Resistance

amikacin; gram-negative bacteria, in vitro, 544

ceftazidime, comparison, ciprofloxacin lactate; pneumonia and urinary tract infections, 49
ciprofloxacin lactate, comparison, ceftazidime; pneumonia and urinary tract infections, 49
Respiratory distress syndrome; pulmonary surfactants; therapy, therapeutic equivalency, 909
Respiratory smooth-muscle relaxants; theophylline; asthma therapy, pediatrics, 685
Restless legs therapy; nocturnal, 427
Rhenium Re 188; radionuclides; monoclonal antibodies, neoplasms, 359
RS-86; Alzheimer's disease; therapy, mechanism of action, review, 447

S

Salsalate; osteoarthritis; therapy, geriatrics, ulcer history, 740
Sargramostim
marketing; FDA approvals, 411
use; evaluation, criteria, 947
Scleroderma; therapy; systemic, 14
Sex; patients; males, toxicity, i.v. infusion sites, 630
Skeletal muscle relaxants
delirium; therapy, intensive-care units, 456
pharmacology; review, mechanically ventilated patients, 32
therapy; nocturnal leg cramps, restless legs, 427
Sorbitol; vehicles; activated charcoal therapy, phenytoin toxicity, liver diseases, 711
Stability
ondansetron hydrochloride; review, 430
phenytoin; blood levels, freezing, ultrafiltration, 132
valproic acid; emulsions, availability, vs. valproate sodium syrup, 382
Staphylococcus aureus; resistance; ciprofloxacin, pneumonia, 49
Steroids; anabolic agents; reclassification, controlled substances, 417
Steroids, cortico; asthma; therapy, pediatrics, 685
Storage; effects; phenytoin; blood levels, ultrafiltration methods, 132
Streptococcus species; resistance; ciprofloxacin, pneumonia, 49
Streptokinase; comparison, alteplase, anistreplase; myocardial infarction therapy, 486
Sucimex
marketing; FDA approvals, controversies, 942
therapy; lead poisoning, 914
Sucralfate; use; evaluation, stress ulcer prophylaxis, criteria, 787
Sufentanil; pharmacology; clinical uses, review, 581
Sufentanil citrate; use; review, criteria, quality assurance programs, 635
Surgical supplies; latex; adverse reactions, FDA recommendations, 417
Sympatholytic agents
β blockers; and doxazosin, hypertension therapy, 9
scleroderma; systemic, therapy, 14
Sympathomimetic agents
asthma; therapy, pediatrics, 685
heart failure; congestive, therapy, diastolic dysfunction, 850
Syrups; valproate sodium; stability, availability, vs. valproic acid emulsions, 382

T

Tacrine hydrochloride; Alzheimer's disease; therapy, mechanism of action, review, 447
Tablets; palatability; cholestyramine, colestipol, oral formulations, 138
Terbutaline sulfate; labor; preterm, home infusion therapy, 292
Tests, laboratory
phenytoin; blood levels, effects, ultrafiltration and freezing, 132
prothrombin; warfarin, interactions, ciprofloxacin, lack, 136
Theophylline; asthma; therapy, pediatrics, 685
Therapy Consultation, 12, 427, 658, 740, 909
Analgesic selection when the patient is allergic to codeine, 658
Comparing surfactant products, 909
Treatment of nocturnal leg cramps and restless leg syndrome, 427
Treatment options for a patient with osteoarthritis and a history of ulcer disease, 740
Use of ketoconazole in the treatment of Cushing's syndrome, 12
Thioridazine hydrochloride; equivalency, generic; brands, comparison, efficacy, quality of life, 938

Thromboembolism
heparin; therapy, guidelines, 503
warfarin; therapy, guidelines, 503
Thrombolytic agents; myocardial infarction; therapy, 486
Tissue levels; mercury; poisoning, pediatrics, 213
Tissue plasminogen activator, see Alteplase
Tocotrienols; terbutaline sulfate; preterm labor, home infusion therapy, 292
Toxicity, environmental
mercury; poisoning, occupational exposure, hyperthyroidism, 742; spills, inhalation, poisoning, pediatrics, 213
meta-analysis; methodology, applications and problems, 4
Toxicity
see also **Drugs, adverse reactions**
acetaminophen; overdose, acetylcysteine therapy, 765
alfentanil hydrochloride; DUE criteria, 635
analgesics; side effects, continuous epidural infusions, 745; side effects, pain therapy, pediatrics, 667
anti-inflammatory agents; osteoarthritis therapy, geriatrics, ulcer history, 740
antineoplastic agents; nausea and vomiting, ondansetron prophylaxis, 430; neutropenia, filgrastim prophylaxis, FDA approvals, 321; ondansetron prophylaxis, FDA approvals, 249
benazepril hydrochloride, 739
botulinum toxin type A; side effects, 88
cardiac drugs; ventricular arrhythmia therapy, 195
chloral hydrate; interactions, furosemide, pediatrics, 385
deferoxamine mesylate; side effects, hemochromatosis therapy, 775
digoxin; therapy, digoxin immune Fab retreatment, immunogenicity, 823
doxazosin mesylate; side effects, hypertension therapy, 9
drugs; lactation, 594
enalapril maleate; DUE criteria, 63
encainide hydrochloride; side effects, product withdrawal, 897
epoetin; DUE criteria, 143, 303
etodolac; side effects, 416
fenantyl; side effects, transdermal patches, pain therapy, 9
fentanyl citrate; DUE criteria, 635
filgrastim; neutropenia prophylaxis, DUE criteria, 950; side effects, 321
fluconazole; DUE criteria, 222; side effects, review, 179
fludarabine phosphate; side effects, 496
furosemide; interactions, chloral hydrate, pediatrics, 385
galium nitrate; side effects, 573
gastrointestinal drugs; stress ulcer prophylaxis, DUE criteria, 787
hetastarch; DUE criteria, 549
injections; i.v. infusion, extravasation, phlebitis, 630
interleukin 2; side effects, neoplasms therapy, 110
isradipine; side effects, 573
ketorolac; tromethamine; DUE criteria, 715
labetalol hydrochloride; side effects, lack, pediatrics, 500
lead; poisoning, succimer therapy, 914
levamisole; side effects, colorectal neoplasms therapy, 95
lorazepam; side effects, high dose, pediatrics, 625
mercury; hyperthyroidism, long-term exposure, 742;
poisoning, pediatrics, 213
midazolam hydrochloride; DUE criteria, 388
misoprostol; DUE criteria, 307
moricizine; arrhythmia therapy, DUE criteria, 873
ondansetron hydrochloride; DUE criteria, 471; side effects, 249; side effects, review, 430
pentamidine; pancreatitis, AIDS, hemophilia, 56
phenytoin sodium; impaired metabolism, liver diseases, 711
ramipril; side effects, 573
sargramostim; DUE criteria, 947; side effects, 411
skeletal muscle relaxants; side effects, mechanically ventilated patients, 32
succimer; side effects, lead poisoning therapy, 914
sufentanil citrate; DUE criteria, 635
terbutaline sulfate; side effects, preterm labor therapy, 292
thrombolytic agents; side effects, myocardial infarction therapy, 486
vaccines; side effects, Vaccine Adverse Event Reporting System, 9
zidovudine; neutropenia, HIV infections, review, 268
Toxins; botulinum toxin type A; dystonia therapy, 88
t-PA, see Alteplase

Tranquilizers; thioridazine hydrochloride; generic equivalency, comparisons, efficacy, quality of life, 938
Transplantation; bone marrow; acute lymphoblastic leukemia patients; sargramostim therapy, FDA approvals, 411; sargramostim therapy, DUE criteria, 947
Triazolam; interactions; ranitidine, pharmacokinetics, 539

Trientine; hepatolenticular degeneration; therapy, 839
Tyloxapol; combination, alcohols, cetyl, colfoscir palmitate; vs. beractant, therapeutic equivalence, 909

U

Ulcers
gastrointestinal drugs; stress, prophylaxis, DUE criteria, 787
misoprostol; gastric, therapy, DUE criteria, 307
prophylaxis; peptic, osteoarthritis, geriatrics, 740
Urinary tract infections
cefazidime, comparison, ciprofloxacin lactate; therapy, apy, 49
ciprofloxacin lactate, comparison, ceftazidime; therapy, apy, 49
Urine levels; mercury; poisoning, pediatrics, 213

V

Vaccine Adverse Event Reporting System; vaccines; adverse reactions and toxicity, reports, 9
Vaccines; toxicity; and adverse reactions, Vaccine Adverse Event Reporting System, 9
Valproate sodium; comparison, valproic acid; stability, availability, emulsions vs. syrups, 382
Valproic acid
comparison, valproate sodium; stability, availability, emulsions vs. syrups, 382
epilepsy; therapy, review, 335
Vancomycin; dosage; guidelines, neonates, 129
Vancomycin hydrochloride; blood levels; half-life, relation creatinine, hepatic and renal dysfunction, 297
Vasodilating agents; heart failure; congestive, therapy, diastolic dysfunction, 850
Vehicles
cholestyramine resin; palatability, oral formulations, preferences, 138
colestipol hydrochloride; palatability, oral formulations, preferences, 138
sorbitol; activated charcoal therapy, phenytoin toxicity, liver diseases, 711
Ventilators; skeletal muscle relaxants; mechanical, patients, effects, 32
Verapamil
angina pectoris; unstable, therapy, 825
muscle cramp; therapy, nocturnal leg cramps, 427
Vitamin E muscle cramp; therapy, nocturnal leg cramps, 427
Volume of distribution, see Drugs, body distribution
Vomiting; ondansetron hydrochloride; therapy, DUE criteria, 471

W

Warfarin
interactions; ciprofloxacin, PT effects, lack, 136
nomograms; dosage, predictions, vs. computers, 923
Weight; patients; predictions, lithium clearance, models, 376

X

Xanthomonas maltophilia; resistance; antibiotics, in vitro, 544
Y

Yttrium Y 90; radionuclides; monoclonal antibodies, neoplasms, 359

Z

Zidovudine; toxicity; neutropenia, HIV infections, review, 268
Zinc; hepatolenticular degeneration; maintenance therapy, 839

Author Index

A

- Allen, Nancy M. Retreatment with digoxin immune Fab (letter), 823
 Altman, Lawrence K. New method of analyzing health data stirs debate (News), 4
 Anderson, Bruce D. see Smith, Leanne B., 132
 Anderson, Philip O. Drug use during breast-feeding, 594
 Antal, Edward J. see Schwinghammer, Terry L., 532
 Ariano, Robert E. Inverse relationship between desmopressin dosage and antidiuresis (letter), 912
 Asher, John P. Use of angiotensin-converting-enzyme inhibitors in the management of renal disease, 25

B

- Bablenis, Elena Effect of use of generic thioridazine products on clinical outcome and quality of life, 938
 Banner, William Jr. Succimer: controversial issues involving the release of a new product (editorial), 942
 Barnett, Michael D. see McGee, Barbara A., 14
 Basile, Sharon A. Criteria for use of heparin, 549
 Baumann, Terry J. Analgesic selection when the patient is allergic to codeine (Therapy Consultation), 658
 Beal, Barbara see Matsuyama, Joy R., 544
 Bennett, Teresa A. Criteria for use of epoetin, 143, 303
 Bennett, Teresa A. Criteria for use of moricizine in adult inpatients and outpatients, 873
 Berardi, Rosemary R. see Knapp, Margaret J., 866
 Bernard, Evelynne see Dellamonica, Pierre, 301
 Bhatt-Mehra, Varsha Management of acute pain in children, 667
 Billeter, Marianne see Rapp, Robert P., 49
 Bombard, Paul A. see Vanderveen, R. Pete, 539
 Bond, William S. Ethnicity and psychotropic drugs, 467
 Botha, Julia H. Estimating phenytoin dosages in black African and Indian children, 928
 Bourne, David W. A. see Hampton, Edward M., 206
 Bourne, Kimberly M. Criteria for use of fluconazole in adult and pediatric inpatients and outpatients, 222
 Buck, Marcia L. Use of nondepolarizing neuromuscular blocking agents in mechanically ventilated patients, 32
 Burwinkle, Joseph W. see Henry, David W., 625

C

- Calis, Karim Anton see Kintzel, P. E., 110
 Carles, Michel see Dellamonica, Pierre, 301
 Carter, Barry L. Therapy of acute thromboembolism with heparin and warfarin, 503
 Carver, Peggy L. see Knapp, Margaret J., 866
 Chae, Joanne S. see Nakahiro, Randall K., 931
 Chaffee, Betty J. Ondansetron—the first of a new class of antiemetic agents, 430
 Check, William A. Conference attendees told ISIS-3 shows equal efficacy, safety differences among thrombolytics (News), 486
 Chin, Alfred see Nakahiro, Randall K., 931
 Clotz, Michael A. Clinical uses of fentanyl, sufentanil, and alfentanil, 581
 Cochran, Emily B. Prediction of serum albumin concentration after albumin supplementation in pediatric patients receiving parenteral nutrition, 704
 Coleman, Robert W. see Fredriks, Dean A., 923
 Coley, Allison L. Criteria for use of enalapril maleate in adults, 63
 Collins, Shelly Rainforth see Gabriel, Mariane Hardenbrook, 129
 Comstock, Thomas J. Book review, 890
 Coonan, Shannon L. see Murphy, Christine M., 685
 Cortese, Linda M. Criteria for use of midazolam hydrochloride in adult patients, 388
 Couch, Patricia Cryoprecipitate for uremic bleeding (letter), 429
 Cox, Steven R. see Vanderveen, R. Pete, 539
 Crisman, M. Lynn see Jermain, Donna M., 376

D

- Davenport, Robertson Cryoprecipitate for uremic bleeding (letter), 429
 Davis, Lisa E. see Spinler, Sarah A., 825

- Dean, Roger P. Interaction of chloral hydrate and intravenous furosemide in a child, 385
 Dellamonica, Pierre Preventing recurrent varicella and herpes zoster with oral acyclovir in HIV-seropositive patients, 301
 Dempsey, Robert J. see Rapp, Robert P., 49
 Dixon, Dennis M. see Kowalsky, Steven F., 179
 Donnelly, Andrew J. see Shafer, Amy L., 745
 Dressman, Jennifer B. see Knapp, Margaret J., 866
 Dufresne, Robert L. see Bablenis, Elena, 938

E

- Eaton, Virginia E. see Rathbun, R. Chris, 280

F

- Fischer, Janet R. Continuous subcutaneous infusion of terbutaline for suppression of preterm labor, 292
 Fish, Douglas N. Treatment of delirium in the critically ill patient, 456
 Fish, Susan S. Book review, 730
 Florentine, Mauro J. Elemental mercury poisoning, 213
 Floridida, Donald G. Book review, 649
 Forrest, Alan see Weidle, Paul J., 711
 Fredriks, Dean A. Nomogram for dosing warfarin at steady state, 923

G

- Gabriel, Mariane Hardenbrook Prospective evaluation of a vancomycin dosage guideline for neonates, 129
 Garabedian-Ruffalo, Susan M. see Saltiel, Emmanuel, 518
 Garewal, Harinder S. see Rindone, Joseph P., 136
 Garnett, William R. see Pugh, Carol B., 335
 Genrich, Jane L. see Gabriel, Mariane Hardenbrook, 129
 Gill, Mark A. see Nakahiro, Randall K., 931
 Gilman, Jamie T. Valproic acid hepatotoxicity in adults and older children (letter), 665
 Goodwin, S. Diane see Bourne, Kimberly M., 222
 Gora, Mary Lea Book review, 805
 Graves, David A. Book review, 970
 Green, Elaine R. Book review, 729

H

- Hackimer, Mary E. see Schwinghammer, Terry L., 532
 Hak, Lawrence J. see O'Neil, Michael G., 56
 Hampton, Edward M. Comparison of MS-DOS and Macintosh pharmacokinetic analysis programs using a two-compartment, two-infusion dosing scheme, 206
 Hartwig, Steven C. Criteria for use of ondansetron hydrochloride in adult and pediatric inpatients and adult outpatients, 471
 Hasegawa, Guy R. Antiarrhythmic monitoring: misplaced emphasis (editorial), 211
 Hatton, Jimmi see Rapp, Robert P., 49
 Hatton, Randy C. see Veerman, Mark W., 382
 Hecker, John see Wright, Alex, 630
 Henry, David W. Determination of sedative and amnestic doses of lorazepam in children, 625
 Hogue, Susan L. see Cochran, Emily B., 704
 Housel, Ben F. see Ishisaka, Denis Y., 500
 Hrdlicka, Kyle see Hampton, Edward M., 206
 Huston, Paul R. see Mutch, Rebecca S., 95

I

- Ishisaka, Denis Y. Labetalol for treatment of hypertension in a child (letter), 500
 Israel, Deb S. Neutropenia in patients infected with human immunodeficiency virus, 268
 Ito, Matthew K. Acceptability of cholestyramine and colestipol formulations in three common vehicles, 138

J

- Jacobi, Judith Book review, 80

- Jermain, Donna M. Population pharmacokinetics of lithium, 376
 Jirak, Jana L. see Vanderveen, R. Pete, 539
 Johanson, Franck see Dellamonica, Pierre, 301
 Johnson, Juli A. Diastolic dysfunction in congestive heart failure, 850
 Johnston, Jann M. see Schwinghammer, Terry L., 532
 Jones, Paul R. see McMorrow, Julie, 501
 Jones, William N. see Rindone, Joseph P., 136

K

- Kaatz, Brian L. see Fischer, Janet R., 292
 Kelleher, Michael D. see Dean, Roger P., 385
 Keller, James H. Book review, 239
 Kelley, Catherine L. see Rindone, Joseph P., 136
 Khanderia, Ujjaini Use of ketoconazole in the treatment of Cushing's syndrome (Therapy Consultation), 12
 Kildow, Carl W. III see Gabriel, Mariane Hardenbrook, 129
 Kintzel, P. E. Recombinant interleukin-2: a biological response modifier, 110
 Kirkling, Marilyn H. Treatment of chronic iron overload, 775
 Klutman, Neil E. see Henry, David W., 625
 Knapp, Margaret J. Modification of gastric pH with oral glutamic acid hydrochloride, 866
 Knight, Matthew E. see Veerman, Mark W., 382
 Kolb, Kenneth W. see Walton, Ted, 427
 Kowalsky, Steven F. Fluconazole: a new antifungal agent, 179
 Kresel, James J. Book review, 243
 Kubacka, Renée T. see Schwinghammer, Terry L., 532

L

- Lackner, Thomas E. A nonexponential, nonlogarithmic, pharmacokinetic dosing method for gentamicin, 706
 Lewis, Richard K. Assessment and treatment of acetaminophen overdose, 765
 Lin, Anne Y. F. Pentamidine-induced facial numbness (letter), 257
 Lokier, François see Dellamonica, Pierre, 301
 Longley, Joyce M. Altered aminoglycoside volume of distribution in patients with acquired immunodeficiency syndrome, 784
 Lopez, Larry M. Verapamil and left ventricular hypertrophy (letter), 333

M

- Mann, Katherine V. Succimer, an oral lead chelator, 914
 Martin, Emory S. III see Jermain, Donna M., 376
 Martin, Emory S. III see also Rathbun, R. Chris, 280
 Martin, J. Kelly Jr. Book review, 976
 Matsuyama, Joy R. Susceptibility of *Xanthomonas maltophilia* and amikacin-resistant gram-negative bacteria to newer antimicrobials, 344
 Matthew, Earl B. see Rathbun, R. Chris, 280
 May, J. Russell Book review, 885
 McCann, Michael Hyperthyroidism associated with mercury poisoning (letter), 742
 McCollam, Patrick L. Evaluation and treatment of ventricular arrhythmias: an update, 195
 McGee, Barbara A. Current options for the treatment of systemic scleroderma, 14
 McGee, Barbara A. see also Small, Ralph E., 870
 McMorrow, Julie Antimicrobial dosages in guidelines for prevention of bacterial endocarditis, 501
 Medina, Richard A. see Peters, Mark D. II, 787
 Mendel, Stephen Book review, 805
 Michael, Katherine A. see Peters, Mark D. II, 787
 Miller, Alan B. see Bennett, Teresa A., 873
 Miller, Donald R. Treatment options for a patient with osteoarthritis and a history of ulcer disease (Therapy Consultation), 740
 Miller, Raymond see Botha, Julia H., 928
 Modanlou, Houchang D. see Gabriel, Mariane Hardenbrook, 129
 Mondain, Véronique see Dellamonica, Pierre, 301
 Moodley, Manikum see Botha, Julia H., 928
 Morreale, Anthony P. see Ito, Matthew K., 138
 Murphy, Christine M. Treatment of asthma in children, 685

Annual Index

Murray, Kim M. Calcium-channel blockers for treatment of diabetic nephropathy, 862
Murray, Kim M. see also Asher, John P., 25
Mutch, Rebecca S. Levamisole in the adjuvant treatment of colon cancer, 95

N

Nahata, Milap C. see Clotz, Michael A., 581
Nahata, Milap C. see also McMorrow, Julie, 501
Nakahiro, Randall K. Use of gentamicin clearance in estimating renal function, 931
Nappi, Jean Trials and tribulations of evaluating ventricular arrhythmias (editorial), 210
Newby, F. David see Longley, Joyce M., 784

O

O'Neil, Michael G. Pancreatitis during pentamidine therapy in patients with AIDS, 56
Okamoto, Mark F. see Nakahiro, Randall K., 931
Orlando, Patricia L. Book review, 885

P

Pachorek, Robert E. Vancomycin half-life in a patient with hepatic and renal dysfunction, 297
Paloucek, Frank P. see Lewis, Richard K., 765
Parish, Roy C. see Pincus, Kelly T., 935
Parker, Robert B. see McCollam, Patrick L., 195
Peloquin, Charles A. Dosage of antimycobacterial agents (letter), 664
Peters, Gary R. see Vanderveen, R. Pete, 539
Peters, Mark D. II Criteria for stress ulcer prophylaxis in intensive-care patients, 787
Pincus, Kelly T. Effect of flurbiprofen and aspirin on platelet aggregation, 935
Pittman, Donald G. see Longley, Joyce M., 784
Plaisance, Karen I. see Israel, Deb S., 268
Porter, Don R. Book review, 316
Prevost, Rebecca Rogers Comparing surfactant products (Therapy Consultation), 909
Price, Karen Overstreet Ethnicity and clozapine-induced agranulocytosis (letter), 743
Pugh, Carol B. Current issues in the treatment of epilepsy, 335
Pugh, Carol B. see also Smith, Leanne B., 132

R

Rapp, Robert P. Intravenous ciprofloxacin versus cefazidime for treatment of nosocomial pneumonia and urinary tract infection, 49
Rathbun, R. Chris Current and investigational therapies for AIDS-associated *Mycobacterium avium* com-

plex disease, 280
Reed, Michael D. see Buck, Marcia L., 32
Reilly, Raymond M. Radioimmunotherapy of malignancies, 359
Rider, Joan M. see Knapp, Margaret J., 866
Rindone, Joseph P. Hypoprothrombinemic effect of warfarin not influenced by ciprofloxacin, 136
Rosen, David A. see Bhatt-Mehta, Varsha, 667
Rudinsky, Brian F. see Dean, Roger P., 385
Rutledge, David R. Which lipid-lowering agent should be used first? 943

S

Saitiel, Emmanuel Pharmacologic management of endometriosis, 518
Sandroni, Stephen see Bennett, Teresa A., 143, 303
Sanfilippo, Dominic J. II see Florentine, Mauro J., 213
Satterlee, Grant B. Criteria for use of fentanyl citrate, sufentanil citrate, and alfentanil hydrochloride, 635
Scheckner, Stuart see McCann, Michael, 742
Scholten, Stephanie L. Correction to AHFS Drug Information 91 (letter), 913
Schwinghammer, Terry L. Pharmacokinetics and pharmacodynamics of glyburide in young and elderly nondiabetic adults, 532
Selar, David A. see Nakahiro, Randall K., 931
Selub, Steven E. see O'Neil, Michael G., 56
Seymour, Beverly see Ariano, Robert E., 912
Shafer, Amy L. Management of postoperative pain by continuous epidural infusion of analgesics, 745
Shepherd, Michele F. Criteria for use of ketorolac tromethamine in adult inpatients and outpatients, 715
Simon, Pamela A. see Murphy, Christine M., 685
Sjolander, Julie A. see Peters, Mark D. II, 787
Skiest, Daniel J. see Weidle, Paul J., 711
Skora, Irene A. see Satterlee, Grant B., 635
Small, Ralph E. Effects of misoprostol or ranitidine on ibuprofen pharmacokinetics, 870
Small, Ralph E. see also McGee, Barbara A., 14
Smith, Candace see Lin, Anne Y. F., 257
Smith, Leanne B. Effect of ultrafiltration product and ultrafiltration-freezing sequence on free phenytoin determination, 132
Spiiner, Sarah A. Advances in the treatment of unstable angina pectoris, 825
Spruill, William J. see Pincus, Kelly T., 935
Stahl-Bayliss, Celine M. Interferon for genital warts (letter), 177
Swanson, Keith A. see Peters, Mark D. II, 787

T

Tami, Joseph A. Recombinant interleukin-2 and the quest for FDA approval, 141
Tankanow, Roberta M. Pathophysiology and treatment of Wilson's disease, 839
Tankanow, Roberta M. see also Chaffee, Betty J., 430
Tartaglione, Teresa see Matsuyama, Joy R., 544
Thom, Claire M. Verapamil and left ventricular hy-

perrophy (letter), 333
Tibbs, Phillip A. see Rapp, Robert P., 49
Todd, Mark W. Criteria for use of misoprostol, 307
Todd, Mark W. see also Bennett, Teresa A., 143, 303
Travers, John D. see Mann, Katherine V., 914
Trotter, J. Mark see Bennett, Teresa A., 873

U

Uden, Don Book review, 650

V

Vanderveen, R. Pete Effect of ranitidine on the disposition of orally and intravenously administered triazolam, 539
Veerman, Mark W. Relative bioavailability and stability of extemporaneously prepared valproic acid emulsion, 382
Volger, Burgunda W. Alternatives in the treatment of memory loss in patients with Alzheimer's disease, 447
Volger, Burgunda W. Book review, 317

W

Wallis, Carolyn see Matsuyama, Joy R., 544
Walton, Ted Treatment of nocturnal leg cramps and restless leg syndrome (Therapy Consultation), 427
Weber, Stanley S. see Bablenis, Elena, 938
Weidle, Paul J. Multiple-dose activated charcoal as adjunct therapy after chronic phenytoin intoxication, 711
Weiss, Peter D. see Lackner, Thomas E., 706
Welty, Timothy E. Book review, 159
Willis, Hayes E. see Small, Ralph E., 870
Wilnot-Pater, Melody G. see Small, Ralph E., 870
Wittkowsky, Ann K. Laboratory monitoring of heparin therapy (letter), 824
Wong, Roberta J. Highlights of the Seventh International Conference on AIDS (News), 809
Wood, Frederick see Pachorek, Robert E., 297
Wright, Alex Infusion failure caused by phlebitis and extravasation, 630

Y

Yamreudeewong, Weeranuj see Lackner, Thomas E., 706
Yonan, Charles D. see Ishisaka, Denis Y., 500
Young, A. Bryon see Rapp, Robert P., 49

Z

Zelesnik, Dee see Matsuyama, Joy R., 544

Advertising Index

A

Adria Laboratories
Idamycin, 5-7, Feb 160, IBC, OBC, Apr 318, IBC, OBC,
Jun 482, IBC, OBC
American Diabetes Association
Institutional, 13, 739
American Lung Association
Institutional, 326
American Society of Hospital Pharmacists
AHFS Drug Information 91, 239, 334, 554
AHFS Drug Information 92, 978
American Journal of Hospital Pharmacy, 629
Aseptic Preparation of Parenteral Products, 67, 238
ASHP Membership, 212, 783, 979
CiteSearch, 256, 416
Clinical Pharmacy, 159, 221, 291, 401, 428, 738
Concepts in Clinical Pharmacokinetics, 317, 741, 969
Concepts in Immunology and Immunotherapeutics,
13, 400, 420
Criteria for Drug Use Evaluation, Volumes 1 and 2,
Jan IFC, 261, 391, 476, 499, 640, 666, 952
European Drug Index, 315, 403, 559, 580
Guidelines for Administration of Intravenous Medications to Pediatric Patients, 548, 990
Handbook on Injectable Drugs, 6th Edition, 232, 302
International Pharmaceutical Abstracts, 231, 358
IV-EASE, 150
Medication Errors: A Closer Look, 744
Medication Teaching Manual, Fourth Edition, 178,
266
MedTeach, 531, 806
Pocket Guide to Injectable Drugs, 1991 Edition, 70,
236, 470, 574
Position Available, 744
QARx, 404, 725
Rx Triage, 267, 387
Safe Handling of Cytotoxic and Hazardous Drugs, 94,
253, 945
Software, 967

Amgen Inc.
Epopen, Sep IFC, Oct IFC, 961-965
Neupogen, 899-908

ASHP Research and Education Foundation
Anticoagulation Clinic Traineeship Program, 557
Awards Program, 75
Institutional, 89, 977

B

Baxter Healthcare Corporation, Hyland Division
Gammagard, 412-414, 488-490
Burroughs Wellcome Company
Exosurf Neonatal, 491-495, 575-579, 659-663, 795-799,
815-819, 971-975
Zovirax I.V., 76-78, 90-92, 240-242, 258-260, 322-324,
408-410, 560-562, 646-648

C

Charleston Area Medical Center
Position Available, 150

D

Department of Veterans Affairs (Richmond)
Positions Available, 73, 83, 163, 265, 325, 415, 563

E

Eisenhower Medical Center
Positions Available, 237, 416, 954

G

Glaxo Inc.
Antiemetic, Feb IFC
Ceptaz, 244-246, 254-256, 398-400
Zofran, 169-174, 327-332, 421-426

H

Harrisburg Hospital
Position Available, 11

I

International Pharmaceutical Federation (F.I.P.)
Membership, 643

K

Kent General Hospital
Position Available, 94

L

Eli Lilly and Company
Hospital Division, 3, 153, Mar IFC, Jun IFC, 485, 813
Lyphomed, Inc.
Amphotericin B, 84-86, 164-166, 262-264

M

Methodist Medical Center of Illinois
Position Available, 497

N

National Easter Seal Society
Institutional, 879
National Foundation for Infectious Diseases
National Forum, 910

P

The Pharmacy Council on Cholesterol
10 Cholesterol Battle Strategies, 502

R

Roche Laboratories, Division of Hoffmann-La Roche, Inc.

Rocephin, Aug IBC, OBC, Oct IBC, OBC, Dec IBC,
OBC

Roerig, A Division of Pfizer Pharmaceuticals
Diflucan, 156-158, 250-252, May IFC, 407, Jul IFC, Aug
IFC, 719-722

Unasyn, 418-420

Ross Laboratories
Survanta, 737-738, 883-884

S

San Francisco VA Medical Center

Position Available, 13

Schering-Plough Corporation

Position Available, 497

SmithKline Beecham

Taganet, Jan IBC, OBC, Mar IBC, OBC, May IBC,
OBC, Jul IBC, OBC, Sep IBC, OBC, Nov IBC, OBC

St. Jude Children's Research Hospital

Institutional, 11, 310, 665

T

Toledo Hospital
Positions Available, 649, 913

U

The University Hospital (Boston)

Position Available, 334

The University of Illinois College of Medicine at Peoria

Positions available, 499

The University of Rhode Island

Position Available, 11

The Upjohn Company

Zefazone, 810-812, 956-958

The Upjohn Company and Chugai-Upjohn, Inc.

Marogen 79, 87, Apr IFC

W

Wyeth-Ayerst Laboratories, Inc.

Ativan Injection, 564-566, 570-572, 654-656, 734-736,

886-888, 894-896

Position Available, 176

Tubex, Nov IFC, Dec IFC